LOTTE BIOLOGICS Announces $100 Million Expansion of ADC Manufacturing Facility
Introduction:
LOTTE BIOLOGICS has signed a manufacturing agreement with a biotechnology company based in Asia for the production of a clinical-stage antibody-drug conjugate (ADC) candidate. This deal represents the first step in offering contract development and manufacturing (CDMO) services for ADCs, ranging from clinical development to commercial production.
Features:
The company aims to deliver integrated, end-to-end services for ADC manufacturing, reinforcing its role in the global ADC therapeutics market.
It includes a complete production and purification line, featuring a conjugation reactor with a capacity of up to 1,000 litres. The site also offers in-house quality control testing, advanced characterisation services, and a single-use system that supports the full ADC manufacturing process, from antibody preparation to aseptic drug substance filling. This setup enables flexibility in responding to diverse client needs.
LOTTE BIOLOGICS aims to ensure a reliable supply of high-quality ADC therapeutics and to enhance its position as a global CDMO with a specialisation in ADCs.
Specifications:
Name : Lotte Biologics
Budget : $100 Million
Type : Expansion
